Avacta Group Investor Relations Material
Latest events
H2 2024
Avacta Group
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Avacta Group PLC
Access all reports
Avacta Group PLC is a biotechnology company specializing in the development of innovative diagnostic and therapeutic solutions. The company operates in two primary segments: diagnostics, where it develops rapid tests and reagents, and therapeutics, focusing on the development of precision oncology treatments. Avacta utilizes proprietary technologies, such as its Affimer platform, to create targeted therapies and diagnostic tools. The company is headquartered in Wetherby, United Kingdom, and its shares are listed on the AIM.
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
AVCT
Country
🇬🇧 United Kingdom